Divalproex Sodium Tablet, Delayed Release
Product Images NDC 87441-027

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 87441-027). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 250 mg (8744102701 Divalproex Sodium 250 mg)

Divalproex sodium delayed release tablets, USP, 250 mg strength. The label indicates the product is for prescription use only and contains enteric-coated delayed-release tablets equivalent to 250 mg valproic acid activity. It includes storage instructions, a pharmacist dispensing notice, and repackager Unit Dose Solutions, Inc. information. The distributor is Tuckahoe Enterprises, LLC.*

FDA Label Image

Divalproex Sodium 500 mg (8744102801 Divalproex Sodium 500 mg)

Label for Divalproex Sodium 500 mg delayed-release tablets, USP, intended for oral use. The label states prescription-only status and includes storage instructions to keep between 20° to 25°C. It is repackaged by Unit Dose Solutions, Inc. and distributed by Tuckahoe Enterprises, LLC. The label also advises pharmacists to dispense the Medication Guide separately to patients.*

FDA Label Image

Image (8928887a 8c8b 4a61 8bc9 A3026d60db17 01)

Chemical structure diagram of the active ingredient Divalproex Sodium, showing its molecular arrangement with sodium ions and organic groups indicated.*

FDA Label Image

Image (8928887a 8c8b 4a61 8bc9 A3026d60db17 02)

A bar chart comparing percentages for two studies labeled 'Study 1 (YMRS)' and 'Study 2 (IMRS)'. Each study shows two bars representing placebo (PBO) and Divalproex Sodium (DVPX), with DVPX bars significantly higher in percentage than placebo.*

FDA Label Image

Image (8928887a 8c8b 4a61 8bc9 A3026d60db17 03)

A line graph comparing the percentage reduction in CPS Rate between Divalproex Sodium and Placebo. The x-axis represents the percentage of patients, and the y-axis shows the percent reduction in CPS Rate with improvement upward and worsening downward. Divalproex Sodium is represented by a solid line, showing greater improvement compared to the dashed line for Placebo.*

FDA Label Image

Image (8928887a 8c8b 4a61 8bc9 A3026d60db17 04)

A cumulative percent reduction in CPS rate chart comparing high dose and low dose treatment groups of Divalproex Sodium delayed-release tablets. The graph plots percentage of patients on the horizontal axis against percent reduction in CPS rate on the vertical axis, indicating patient improvement or worsening.*

FDA Label Image

Image (8928887a 8c8b 4a61 8bc9 A3026d60db17 05)

A bar chart comparing two studies that show a measure on the vertical axis for Placebo versus Divalproex Sodium. Study 1 shows a higher value for Placebo compared to Divalproex Sodium. Study 2 also shows a higher value for Placebo compared to Divalproex Sodium, but both studies show a decrease from Placebo to Divalproex Sodium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.